Out Fox The $treet

  Viking Therapeutics' stock plunged over 40% after misunderstood Phase 2 oral weight-loss drug data, despite results showing strong short-term efficacy versus market leaders. The Phase 2 trial demonstrated 12.2% weight loss in 13 weeks, with progressive results and potential for further improvement with longer dosing periods. Concerns over high discontinuation and GI side effects are noted, but these issues are manageable and expected to be addressed in Phase 3 studies. The market's reaction is a major overreaction; I remain ultra bullish on VKTX stock, as the investment thesis is de-risked and the pipeline is well-funded for future growth. Viking Therapeutics, Inc.  ( NASDAQ: VKTX ) plunged after the market wildly misinterpreted Phase 2 data for a key weight loss drug. The biotech continues to progress to a pivotal Phase 3 study while de-risking the strong pipeline. My  investment thesis  remains ultra Bullish on the stock, especially after Viking Therapeutics fell...

  Viking Therapeutics' hit yearly lows despite strong sector expectations, as it enters pivotal trials for obesity drugs. The biotech announced a production deal with CordenPharma, signaling confidence in FDA approval and eliminating the need for capital-intensive manufacturing facilities. The $150 million prepayment deal with CordenPharma ensures production capacity ensures production capacity for 1 billion oral tablets and billions in annual revenues. The stock only has a market cap of $3 billion after this dip, despite the potential for billions in sales and a peer trading at 12.5x sales targets. The obesity drug sector has taken a significant hit despite ongoing strong expectations for weight-loss drugs. The sector dip has left  Viking Therapeutics, Inc.  ( NASDAQ: VKTX ) at yearly lows just as the biotech enters pivotal trials for their  obesity drugs. My  investment thesis  remains ultra-Bullish on the stock following the latest dip and game-changing ...